Related references
Note: Only part of the references are listed.FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
Daniel L. Suzman et al.
ONCOLOGIST (2019)
Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study
Rui Batista et al.
FRONTIERS IN GENETICS (2019)
Diagnostic accuracy of the UBC® Rapid Test for bladder cancer: A meta-analysis
Pei Lu et al.
ONCOLOGY LETTERS (2018)
UBC® Rapid Test-A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study
Thorsten H. Ecke et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Marko Babjuk et al.
EUROPEAN UROLOGY (2017)
Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis
Zijie Wang et al.
ONCOTARGET (2017)
Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis
Aiye Guo et al.
CUAJ-Canadian Urological Association Journal (2014)
Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer
Bernd J. Schmitz-Draeger et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2013)
Considerations on the use of diagnostic markers in management of patients with bladder cancer
Piyush K. Agarwal et al.
WORLD JOURNAL OF UROLOGY (2008)
Molecular alterations associated with bladder cancer progression
Marta Sanchez-Carbayo et al.
SEMINARS IN ONCOLOGY (2007)
Genetic alterations in urothelial bladder carcinoma - An updated review
P Mhawech-Fauceglia et al.
CANCER (2006)
Discovery and validation of new protein biomarkers for 4 urothelial cancer: a prospective analysis
D Theodorescu et al.
LANCET ONCOLOGY (2006)
Propensity score approach to estimating the cost - effectiveness of medical therapies from observational data
N Mitra et al.
HEALTH ECONOMICS (2005)
FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas:: Independent distribution and lack of association with prognosis
S Hernández et al.
CLINICAL CANCER RESEARCH (2005)
The 2004 WHO classification of bladder tumors: A summary and commentary
R Montironi et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2005)
FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma
BSW van Rhijn et al.
CANCER RESEARCH (2004)
Non-invasive urothelial neoplasms: According to the most recent WHO classification
A Lopez-Beltran et al.
EUROPEAN UROLOGY (2004)
The health economics of bladder cancer - A comprehensive review of the published literature
MF Botteman et al.
PHARMACOECONOMICS (2003)
Share Paper
